Navigation Links
AQUA® Technology Expands to Additional Digital Pathology Platform with Launch of Vectra™ 2 from Caliper Life Sciences, a Perkin-Elmer Company
Date:11/17/2011

SAN FRANCISCO, Nov. 17, 2011 /PRNewswire/ -- Caliper® Life Sciences, a Perkin-Elmer Company, launched their new Vectra™ 2 with AQUA technology, an integrated solution for quantification of protein biomarkers in tissue, at the Molecular Targets & Cancer Therapeutics meeting here this week.  Caliper and HistoRx® collaborated on this new immunofluorescent imaging and analysis solution that will deliver objective, quantitative, and reproducible results: an improvement on traditional immunohistochemistry.  The new product enables users to leverage the combined imaging and analysis power of Caliper's Vectra 2, an automated multiplexed and multispectral tissue imaging platform, and AQUA® technology, HistoRx's proprietary image analysis system, to provide an integrated solution to advance the identification and validation of new drug targets and improve assessment of drug response.  

"The Vectra 2 with AQUA technology represents a significant move forward for those interested in digital pathology with both brightfield and fluorescent capabilities," said Mark Gustavson, Ph.D., Director of Operations at HistoRx.  "By matching AQUA technology's fluorescence-based quantitative measurement with Caliper's market-leading multispectral imaging capabilities, users will be afforded a level of quality, performance and reproducibility that is unparalleled.  Caliper has outdone itself with enhancements to its earlier product, while HistoRx has ensured that customer needs for high-volume digital fluorescence analysis are addressed through AQUAServe™."

AQUAServe is a new server-based queuing software designed to enable 'walk-away' operation for multiple specimens while retaining the full functionality of HistoRx's flagship AQUAnalysis™ software.  AQUAServe will enable high-volume customers to take full advantage of Vectra's 200-slide loader.  Caliper will distribute the integrated product in the research market; the companies are also exploring collaborations in clinical research and diagnostics. Caliper and Vectra are trademarks of Caliper Life Sciences.

About HistoRx, Inc.

HistoRx, Inc. is a leading developer of tissue-based diagnostic solutions to advance individualized patient care.  The company's products and services are based on proprietary analysis of tissue biomarkers using AQUA technology.  AQUA technology is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, reproducible, and automated analysis to guide drug development and therapeutic decision-making.  HistoRx is commercializing proprietary diagnostic products targeting improved treatment decision-making and patient outcomes in cancer care.  AQUA is a registered trademark of HistoRx, Inc.  For more information, please visit www.historx.com.


'/>"/>
SOURCE HistoRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Clarient Joins the HistoRx® Clinical Trials Network: First Commercial Lab to Provide Aqua® Technology for Clinical Trials
2. HistoRx Announces Launch of New Research Services: AQUAPrep™ and Access AQUA® Services Now Available
3. HistoRx Announces First Clinical Diagnostic Use of AQUA® Technology
4. PharmAthene to Present at the 2011 Chemical and Biological Defense Science and Technology Conference
5. Awarepoint Advances Industry Leadership with New Patented Technology
6. Intergraph® Technology Enables Bayer Technology Services to Engineer New Plant in China
7. Bend Research Signs Technology Licensing Agreement with Merck
8. GeckoSystems Actively Negotiating Joint Venture with Chinese Wheelchair Manufacturer for International Marketing of Robotic Wheelchair Safety Technology
9. New Web Technology Now Allows for Pharmaceutical Reps to Receive Training on Their Desktops, Tablets, and Smartphones
10. Campden Publishing Unveils new Med Comms Division and World-First Technology Licence
11. Inova Labs Announces Launch of the LifeChoice Portable Oxygen Concentrator With Auto Mode Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016 According to responses from U.S. oncologists that ... of patients with non-small cell lung cancer (NSCLC), treatment decisions ... genetic mutation status. The findings of the survey were presented ... #P3.02b ) at the 2016 World Conference on Lung ... The survey results revealed an overall high rate of ...
(Date:12/7/2016)... Dec. 7, 2016 Boehringer Ingelheim today ... patients with unresectable malignant pleural mesothelioma (MPM) met ... data, presented at the 17 th IASLC ... Vienna , showed nintedanib plus pemetrexed/cisplatin demonstrated ... pemetrexed/cisplatin, with a significantly improved PFS (9.4 vs ...
(Date:12/7/2016)... YORK , December 7, 2016 ... Pharmaceuticals PLC (NASDAQ: JAZZ ), Anthera Pharmaceuticals Inc. ... DNAI ), and AveXis Inc. (NASDAQ: AVXS ... Sector Index fell roughly 37% to reach a level equal ... it is down by approximately 14% for the year, it ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... , ... AlignLife clinics nationwide are giving back to their communities by collecting ... bountiful gifts wrapped tightly under a Christmas Tree. AlignLife hopes to spread the ... , In exchange for generous donations, customers will receive a gift in return. ...
(Date:12/7/2016)... ... December 07, 2016 , ... Sharon Kleyne, host of the ... and Your Health on Voice of America, declared on her radio program in November ... the fact that when these bullies attack leaders in corporate America, they are trying ...
(Date:12/7/2016)... ... , ... Delete® - Tattoo Removal and Laser Salon Offers Delightful Holiday Deals ... To 33% Off Botox® and Juvederm® Products Now Through December 31, 2016 , Delete® ... Deals on Botox® and Juvederm® just in time for the holiday party season. ...
(Date:12/7/2016)... ... 2016 , ... The medical profession is well aware that heart attacks do ... analyzing heart attacks among 138,602 people recorded a 35% higher number of heart attacks ... agree of course–no time of year is a good time for a heart attack! ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... its newest portable bioelectronic medicine device WellnessPro Plus for consumers and healthcare ... enhances the WellnessPro platform by expanding the treatment modalities available in a ...
Breaking Medicine News(10 mins):